During the past decade, Ocala Research Institute, Inc conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ocala Research Institute, Inc" #1 sponsor was "George Medicines PTY Limited" with 2 trials, followed by "Sanofi" with 2 trials sponsored, "Abbott Nutrition" with 1 trials sponsored, "Amgen" with 1 trials sponsored and "Bristol-Myers Squibb" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ocala Research Institute, Inc" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator, "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator and "United States Department of Defense" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Ocala Research Institute, Inc" are "Hypertension" (3 trials), "Acute Coronary Syndrome" (1 trials), "Angioplasty, Transluminal, Percutaneous Coronary" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Ocala Research Institute, Inc" in a lesser frequency.

Most popular intervention types in "Ocala Research Institute, Inc" are "Drug" (13 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg" (2 trials), "ACE-I (lisinopril) or ARB (losartan)" (1 trials), "Amlodipine 2.5 mg/indapamide 1.25 mg" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ocala Research Institute, Inc" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Ocala Research Institute, Inc". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Ocala Research Institute, Inc, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ocala Research Institute, Inc, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".